BTA injections can treat infantile esotropia

Article

Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia.

Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia, claims a paper in the journal Eye.

The investigation, led by Dr J. Chen, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, China, included 47 patients with infantile esotropia who were randomly divided into two groups. Group A included 23 cases treated with bilateral injection of 2.5–3.75 U BTA combined with sodium hyaluronate (SH). In group B 24 patients were administered the BTA solution with SH. All patients did not undergo electromyography and injections were evaluated two weeks, three months and six months postoperatively.

Both groups presented with good alignment six months after injections, with group A at 30.4% and group B at 37.5%. Complicated ptosis and vertical deviation were 2.2% vs 20.8% and 2.2% vs 2.1% in groups A and B, respectively.

BTA injections with or without SH produced similar results and demonstrated effectiveness and feasibility. However, BTA injections with SH relatively decrease the frequency of complicated ptosis.

The abstract can be read here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.